References
- Thomas E D. Bone marrow transplantation: a review. Seminars in Hematology 1999; 36(4 Suppl7)95–103
- Odom L F, August C S, Githens J H, Humbert J R, Morse H, Peakman D, et al. Remission of relapsed leukemia during a graft versus host reaction. A graft versus leukemia reaction in man?. Lancet 1978; 2: 537–540
- Kolb H J, Schattenberg A, Goldman J M, Hertenstein B, Jacobsen N, Arcese W, et al. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft versus leukemia effect of donor lymphocyte infusions in marrow graftred patients. Blood 1995; 86: 2041–2050
- Storb R, Yu C, Wagner J L, Deeg H J, Nash R A, Kiem H P, Leisenring W, Shulman H. Stable mixed hematopoietic chimersim in DLA—identical littermate dogs given sublethal body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048–3054
- Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P, et al. Allogeneic bone marow transplantation vs. filgrastim—mobilised peripheral blood progentitor cell transplantation in patients with early leukemia: first results of a randomised multicenter trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995–1003
- Storb R, Deeg H J, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukaemia. New England Journal of Medicine 1986; 314: 729–735
- Meyers J D, Reed E C, Shepp D H, Thornquist M, Dandliker P S, Vicary C A, et al. Acyclovir for prevention of cytomegslovirus infection and disease after allogeneic marrow transplantation. New England Journal of Medicine 1988; 318: 70–75
- Bowden R A, Slichter S J, Sayers M H, Mori M, Cays M J, Meyers J D. Use of leukocyte-depleted platelets and cytomegalovirus—seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78: 246–250
- Niederwieser D, Maris M, Shizuru J A, Petersdorf E, Hegenbart U, Sandmeier B M, et al. Low dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA—matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimersim and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620–1629
- The Joint Accreditation Committee of ISHAGE-Europe and EBMT, Standards for blood and marrow progenitor cell processing, collection and transplantation. 1998
- Reichert T, DeBruyere M, Deneys V, Totterman T, Lydyard P, Yuksel F, et al. Lymphocyte subset reference ranges in adult Caucasians. Clinical Immunology & Immunopathology 1991; 60: 190–208
- Storek J, Wells D, Dawson M A, Storer B, Maloney D G. Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood 2001; 98: 489–491
- Saito T, Kanda Y, Nakai K, Kim S W, Arima F, Kami M, et al. Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation. Bone Marrow Transplant 2003; 32: 601–608
- Hakki M, Riddell S R, Storek J, Carter R A, Stevens-Ayers T, Sudour P, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003; 102: 3060–3067
- Maris M, Boeckh M, Storer B, Dawson M, White K, Keng M, et al. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Experimental Hematology 2003; 31: 941–952